Novo Nordisk is working with GoodRx to offer a month’s supply of Ozempic for $499, or about half the list price, for self-paying patients.
Ozempic, a drug approved for Type 2 diabetes, cardiovascular disease and kidney disease, has a list price of $997. Wegovy, which is indicated for weight loss, cardiovascular disease and liver disease, costs $1,349 for a four-week supply.
As of Aug. 18, all strengths of both GLP-1 medications are available for $499 per month for self-paying patients.
More than 70,000 U.S. retail pharmacies are participating in the offering, according to GoodRx and Novo Nordisk.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
